Efficacy of a mitochondrion-targeting agent for reducing the level of urinary protein in rats with puromycin aminonucleoside-induced minimal-change nephrotic syndrome

Yuko Fujii, Hideki Matsumura, Satoshi Yamazaki, Akihiko Shirasu, Hyogo Nakakura, Tohru Ogihara, Akira Ashida

1 Department of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan, 2 Department of Pediatrics, Hirakata City Hospital, Hirakata, Osaka, Japan, 3 Department of Hemodialysis and Apheresis, Arisawa General Hospital, Hirakata, Osaka, Japan

* ped006@osaka-med.ac.jp

Abstract

Background
Oxidative stress is a major factor responsible for minimal-change nephrotic syndrome (MCNS), which occurs most commonly in children. However, the influence of oxidative stress localized to mitochondria remains unclear. We examined the effect of a mitochondrion-targeting antioxidant, MitoTEMPO, in rats with puromycin aminonucleoside (PAN)-induced MCNS to clarify the degree to which mitochondrial oxidative stress affects MCNS.

Materials and methods
Thirty Wistar rats were divided into three groups: normal saline group (n = 7), PAN group (n = 12), and PAN + MitoTEMPO group (n = 11). Rats in the PAN and PAN + MitoTEMPO groups received PAN on day 1, and those in the PAN + MitoTEMPO group received MitoTEMPO on days 0 to 9. Whole-day urine samples were collected on days 3 and 9, and samples of glomeruli and blood were taken for measurement of lipid peroxidation products. We also estimated the mitochondrial damage score in podocytes in all 3 groups using electron microscopy.

Results
Urinary protein excretion on day 9 and the levels of lipid peroxidation products in urine, glomeruli, and blood were significantly lower in the PAN+MitoTEMPO group than in the PAN group (p = 0.0019, p = 0.011, p = 0.039, p = 0.030). The mitochondrial damage score in podocytes was significantly lower in the PAN+MitoTEMPO group than in the PAN group (p <0.0001).
Conclusions

This mitochondrion-targeting agent was shown to reduce oxidative stress and mitochondrial damage in a MCNS model. A radical scavenger targeting mitochondria could be a promising drug for treatment of MCNS.

Introduction

It has recently become evident that mitochondrial damage is associated with a wide range of conditions affecting the brain [1], cardiovascular system [2], lungs [3], digestive tract [4] and liver [5], as well as in metabolic diseases and neoplasia [6]. Mitochondrial damage is also implicated in various conditions affecting the kidney, such as acute kidney injury due to sepsis [7], chemical agents [8] or other substances [9, 10], congenital nephrotic syndrome [11], focal segmental glomerulosclerosis [12–15], diabetic nephropathy [16], acute or chronic interstitial nephritis [17], chronic kidney disease [18], and transplanted kidney grafts [19, 20].

(2-(2,2,6,6-Tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl) triphenylphosphonium chloride (MitoTEMPO) is a mitochondrion-targeting radical scavenger [2, 7, 20–23]. The positive charge carried by the triphenylphosphonium component enables MitoTEMPO to pass through the lipid bilayer into the mitochondrial matrix, where it accumulates to a concentration 1000-fold higher than in other areas [23]. Mitochondria consume as much as approximately 85% of the total amount of oxygen required by the cell to produce adenosine triphosphate, at the same time producing large amounts of reactive oxygen species (ROS) and lipid oxidation products [24]. As the TEMPO component of MitoTEMPO scavenges ROS such as superoxide dismutase, it can improve the status of many mitochondrion-associated diseases [23].

Rats given a single injection of puromycin aminonucleoside (PAN) constitute a well-established model of minimal-change disease [25]. The pathology of PAN-induced minimal-change nephrotic syndrome (MCNS) has been explained in terms of podocyte damage and apoptosis due to a ROS surge [25, 26]. We have previously reported that alpha-tocopherol and edaravone, radical scavengers that inhibit lipid peroxidation, reduce ROS in rats with PAN-induced MCNS [27, 28]. Recently, it has become evident that α-tocopherol and edaravone also exert a favorable effect on mitochondria [29, 30]. These observations, as well as the fact that mitochondria produce large amounts of ROS, suggest that PAN-induced MCNS may be intimately associated with mitochondrial damage.

Although a few reports have suggested that mitochondrial damage may underlie MCNS, to our knowledge those studies all involved an in vitro approach [31, 32]. In the present in vivo study, therefore, we investigated whether mitochondrial damage is one of the major causes of PAN-induced MCNS.

Materials and methods

Ethics statement

All of the present experiments were conducted in accordance with the protocol for treatment of experimental animals at Osaka Medical College. The experimental protocol, including ethical aspects, was approved by the Osaka Medical College Animal Care and Use Committee (approval numbers: 28054, 29057). All necropsy procedures were performed soon after
euthanasia with an overdose of intraperitoneal sodium pentobarbital and all efforts were made to minimize suffering.

**Reagents**

PAN and MitoTEMPO were purchased from Sigma-Aldrich, St. Louis, MO, USA. PAN was diluted in 0.9% normal saline (NS) to a concentration of 10 mg/mL at the time of use. MitoTEMPO was diluted in 0.9% NS to a concentration of 1.0 mg/mL on day 0, stored at 4˚C, and on day 2 it was diluted to 0.2 mg/mL in 0.9% NS.

**Experimental animals**

Thirty male Wistar rats, 6 weeks of age, weighing 120–150 g (Japan SLC, Shizuoka, Japan) were housed in metabolic cages and given free access to commercial feed (Oriental Yeast, Tokyo, Japan) and water. They were divided into three groups: NS group (n = 7), PAN group (n = 12), and PAN + MitoTEMPO group (n = 11). PAN (5 mg/100 g body weight) was injected subcutaneously on day 1 [27]. MitoTEMPO was injected intraperitoneally at a dose of 0.5 mg/100 g body weight on days 0 to 1, and then at 0.07 mg/100 g body weight on days 2 through 9 [2, 7, 22]. 0.9% NS was used as a placebo. Whole-day urine samples were collected from these rats on days 3 and 9, and stored at -80˚C. The rats were sacrificed on day 10, and samples of glomeruli and blood plasma were taken and stored at -80˚C. These samples were used for measurement of protein, creatinine, and 2-thiobarbituric acid-reactive substances (TBARS), as reported previously [27]. We calculated creatinine clearance (mL/min/kg) from the data according to the formula: (UV x Ucr) / (Pcr x 1000), where UV = urine volume (μL/min/kg), Ucr = urinary creatinine (mg/dL), and Pcr = plasma creatinine (mg/dL). Randomly obtained plasma samples (n = 4, 4, 4, respectively) were also subjected to measurement of 4-hydroxynonenal (4HNE) concentration using negative-ion chemical ionization gas chromatography-mass spectrometry as oxime-tert-butylidimethylsilyl derivatives with an internal standard of 2,2,6,6-d4-cyclohexanone using a Shimadzu QP-5050A system (Shimadzu, Kyoto, Japan), as reported previously [33]. As another marker of oxidative stress, the plasma dityrosine concentration (n = 7, 8, 8) was also measured from randomly chosen samples, as described previously [33]. The data were expressed as ratios relative to the parent molecule, para-tyrosine (nmol/μmol x 10^2).

**Light microscopy and immunohistochemical analysis**

Upon sacrifice on day 10, the left kidney was removed from each rat. Paraffin-embedded sections of formalin-fixed kidney tissue were prepared after deparaffinization in xylene. Some were subjected to periodic acid-Schiff staining using a standard procedure, and others were used for immunohistochemical analysis of 4HNE or cleaved caspase-3. The latter were dehydrated by serial immersion in 100% ethanol, 90% ethanol, 70% ethanol, and water, then antigen retrieval was conducted by heating in a microwave oven followed by washing with phosphate-buffered saline (PBS). Endogenous peroxidase activity was reduced by immersion in 3% hydrogen peroxide. After rinsing, sections were covered in 3% goat serum for 30 minutes and incubated with 25 μg/mL murine-derived anti-4-HNE monoclonal antibody (NIKEN SEIL, Tokyo, Japan) diluted in PBS (1:50) overnight. After incubation, the sections were rinsed with PBS and incubated with biotin-labeled secondary antibody diluted 1:300 in PBS for 2 hours. After incubation with the secondary antibody, the sections were rinsed with PBS, incubated in ABC complex (Vector Laboratories, Burlingame, CA, USA) for 30 minutes at room temperature, rinsed in PBS, and developed with diaminobenzidine and hydrogen peroxide. Slides were lightly counterstained with hematoxylin, then dehydrated by sequential
immersion in 70% ethanol, 90% ethanol, 100% ethanol, and xylene before applying coverslips. For assessment of glomeruli, each section was visualized using a Nikon Eclipse 80i microscope with a ×40 objective and captured as a TIFF image using a DS-Ri1 digital camera (Nikon, Tokyo, Japan). We observed all of the glomeruli visible on each slide to evaluate the location of peroxidation. For cleaved caspase-3 staining, we employed the same protocol using a 2000-fold diluted anti-cleaved caspase-3 antibody (Cell Signaling Technology, Denver, MA, USA) as the primary antibody. All glomeruli from each group, as far as we could observe using the light microscope, were photographed to count the number of positive cells in each glomerulus.

**Electron microscopy**

Part of the left kidney from two different rats in the PAN group and PAN + MitoTEMPO group, and a single rat in the NS group, was randomly chosen, prefixed in 2% glutaraldehyde in 0.1M PBS (pH 7.4) for 3 hours, then post-fixed in 1% osmium tetroxide in 0.1M PBS at 4°C for 2 hours. The fixed samples were washed five times in 0.1M PBS and dehydrated through a graded ethanol series for 15 minutes each. They were then embedded in epoxy resin and processed using a regular procedure for electron microscopy. Ultrathin sections were cut with an ultramicrotome (ULTRACUT-N, Reichert-Nissei, Tokyo, Japan) and mounted on a 200-mesh copper grid supported by a carbon-coated collodion film. They were then double-stained with uranyl acetate and lead citrate. A non-expert in nephrology unrelated to the present study observed the specimens with a transmission electron microscope (H-7650 types, Hitachi, Tokyo, Japan) and took photographs of randomly chosen podocytes (n = 5, 18, 10, respectively) and their foot processes.

We then used the images to score the degree of mitochondrial damage for all of the mitochondria visible in each podocyte (n = 4–41 per podocyte) and calculated the average score for each podocyte. The method used in the present study for scoring of mitochondrial damage was reported previously by Sesso et al. [34] and Sweetwyne et al. [35], who observed mitochondria in preapoptotic and apoptotic cells using electron microscopy and categorized the mitochondria into 5 groups. Score 1: No obvious damage, clear inner and outer membranes with a dense matrix and regularly aligned cristae. Score 2: Crista membranes disrupted with occasional vacuolation, the matrix mostly remaining dense. Apparent separation of the inner and outer mitochondrial membranes. Score 3: Mitochondrial matrix largely diminished with few remaining cristae. Score 4: Cristae mostly absent. Matrix either absent or very electron dense, and evident rupture of some outer membranes. Score 5: Triple and quadruple membrane rings indicative of autophagy or mitophagy evident.

**Statistical analysis**

The data were expressed as the median and interquartile range (IQR). We used the Kruskal-Wallis test and the Wilcoxon test to compare differences among the groups, and p < 0.05 was considered the level of significance. All statistical analyses were performed using JMP Pro 13 software (SAS Institute, Cary, NC, USA).

**Results**

**Daily urinary protein**

In the present study, the daily level of urinary protein increased from days 3 to 9 in both the PAN group and the PAN + MitoTEMPO group (Fig 1). The level of daily urinary protein on day 3 showed no significant differences among the groups, but on day 9 it was 20.5 (IQR 16.2–
Mitochondrial damage in a model of minimal change nephrotic syndrome

35.7), 265.3 (IQR 144.0–371.7), and 87.5 (IQR 76.1–138.7) mg/day in the NS, PAN, and PAN + MitoTEMPO groups, respectively, being significantly lower ($p = 0.0019$) in the PAN + MitoTEMPO group than in the PAN group (Fig 1).

Kidney function

The levels of creatinine clearance at sacrifice were 113.9 (IQR 75.4–168.7), 100.7 (IQR 73.8–125.7), and 76.5 (IQR 65.8–118.3) mL/min/kg in the NS, PAN, and PAN + MitoTEMPO groups, respectively, showing no significant differences among the groups.

Lipid peroxidation

The levels of urinary TBARS on day 9 relative to creatinine were significantly lower ($p = 0.011$) in the PAN + MitoTEMPO group (8.3, IQR 6.1–11.5 nmol/mgCr) than in the PAN group (12.5, IQR 11.4–15.5 nmol/mgCr) (Fig 2A). The levels of glomerular TBARS relative to protein were significantly lower ($p = 0.039$) in the PAN + MitoTEMPO group (1.5, IQR 1.2–1.6 x10² nmol/mg protein) than in the PAN group (1.8, IQR 1.6–1.7 x10² nmol/mg protein) (Fig 2B). The levels of plasma 4HNE at sacrifice in randomly chosen samples were significantly lower ($p = 0.030$) in the PAN + MitoTEMPO group (6.8, IQR 3.0–8.9 nmol/L) than in the PAN group.
The levels of plasma dityrosine at sacrifice tended to be lower ($p=0.06$) in the PAN + MitoTEMPO group (3.1, IQR 2.5–3.58 nmol/μmol x 10$^2$) than in the PAN group (4.6, IQR 3.7–5.4 nmol/μmol x 10$^2$) (Fig 2D).

We detected anti-4HNE monoclonal antibody staining in podocytes in the PAN group. Representative images of samples in each group are shown in Fig 3.

**Light microscopy evaluation of the kidney tubulointerstitium, glomeruli, and podocyte apoptosis**

Histological evaluation using light microscopy revealed only minor glomerular abnormalities and no major damage to the kidney tubulointerstitium. The mean number of cells positive for cleaved caspase-3 per glomerular section was 0.051, 0.33, 0.14 in the NS, PAN, and PAN + MitoTEMPO groups, respectively. Representative images of staining for cleaved caspase-3 in each group are shown in Fig 4.

**Evaluation by electron microscopy**

Effacement of podocyte foot processes was evident in the glomerular sample from the PAN group, and also partially evident in the PAN + MitoTEMPO group (Fig 5). The daily urinary

---

**Fig 2. Oxidative stress markers.** Reactive oxygen species at sacrifice in the NS, PAN, PAN + MitoTEMPO groups. (A) The levels of urinary TBARS/creatinine (nmol/mgCr) were measured by the method of Yagi. (B) The levels of glomerular TBARS ($x10^2$ nmol/mg protein) were measured by the method of Beug and Aust. (C) The levels of plasma 4HNE (nmol/L) and (D) plasma dityrosine as ratios relative to the parent molecule, para-tyrosine (nmol/μmol x 10$^2$), in randomly chosen samples (NS, PAN, PAN + MitoTEMPO; n = 4, 4, 4, and n = 7, 8, 8, respectively) were measured using negative-ion chemical ionization gas chromatography-mass spectrometry. Reactive oxygen species in rats with PAN-induced minimal-change nephrotic syndrome were decreased by treatment with MitoTEMPO. Data are expressed as the median and inter-quartile range. PAN = puromycin aminonucleoside; TBARS = 2-thiobarbituric acid-reactive substances; 4HNE = 4-hydroxynonenal; NS = normal saline; n.s. = not significant.

https://doi.org/10.1371/journal.pone.0227414.g002

(12.0, IQR 11.0–16.0 nmol/L) (Fig 2C). The levels of plasma dityrosine at sacrifice in randomly chosen samples tended to be lower ($p=0.06$) in the PAN + MitoTEMPO group (3.1, IQR 2.5–3.58 nmol/μmol x 10$^2$) than in the PAN group (4.6, IQR 3.7–5.4 nmol/μmol x 10$^2$) (Fig 2D).
protein level and the foot process effacement in the PAN group were consistent with PAN nephrosis; a higher mean mitochondrial damage score in podocytes was correlated with more evident foot process effacement relative to other areas.

The mitochondrial damage score was significantly lower ($p < 0.0001$) in the PAN + MitoTEMPO group (1.2, IQR 1.1–1.4) than in the PAN group (1.8, IQR, 1.6–2.0) (Fig 6). Some representative images of mitochondria in each group are shown in Fig 7. Mitochondria assigned a worse score were more evident in the PAN group than in the other groups.

**Discussion**

**Relationship between PAN-induced MCNS and mitochondrial ROS**

Minimal-change disease is a major type of nephrotic syndrome in children, and a well-established rat model of MCNS induced by a single injection of PAN is available. As Gwinner et al.,
have reported that ROS production in glomeruli continues until 9 days after a single PAN injection [25], many researchers have investigated PAN-induced MCNS in relation to ROS production [25, 26]. This has led to a search for antioxidant agents that can ameliorate the disease state of PAN-induced MCNS, and several ROS scavengers have been reported [26]. We have also shown that $\alpha$-tocopherol and edaravone are promising antioxidants that can ameliorate PAN-induced MCNS in vivo [27, 28]. More recently, it has become clear that other kidney diseases appear to be associated with mitochondrial damage and ROS.

While few reports have focused on minimal-change disease, Shen et al. showed that mitochondrial damage was ameliorated in murine podocytes cultured with PAN after pretreatment with cyclosporin A and tacrolimus [31]. Shen’s work and a few other studies have suggested that, in vitro, mitochondrial damage leads to podocyte apoptosis, suggesting that the latter could lead to proteinuria in vivo [31, 32]. However, whether or not mitochondrial damage actually occurs in an experimental animal model of MCNS, such as that induced by PAN, and the degree to which urinary protein can be decreased by mitochondrial scavenging therapy are issues that have remained unclear.

Here, using a single in vivo experimental model, we investigated the degree to which a mitochondrial-targeting ROS scavenger, MitoTEMPO, was able to ameliorate mitochondrial damage and reduce mitochondrial ROS and daily urinary protein excretion. As shown in Fig 1, the daily urinary protein excretion in the PAN + MitoTEMPO group was significantly decreased...
relative to the PAN group. The antioxidative effect of MitoTEMPO was equivalent to that of edaravone, which we had reported previously [28]. Fig 2 shows that the levels of TBARS in urine on day 9, TBARS in glomeruli, and 4HNE at sacrifice were significantly decreased in the PAN + MitoTEMPO group relative to the PAN group. Immunohistochemical staining demonstrated more frequent 4HNE staining of podocytes and podocyte apoptosis in the PAN group, consistent with previous reports and our assumptions. Thus, it was proved that specific scavenging of mitochondrial ROS by MitoTEMPO led to a decrease of both ROS production and daily urinary protein excretion.

Our next step was to demonstrate that not only was mitochondrial ROS scavenged by MitoTEMPO in the mitochondrial matrix, but also that mitochondrial damage was related to the increase of mitochondrial ROS and urinary protein. Therefore, using transmission electron microscopy, we studied the morphology of mitochondria to assess the degree of mitochondrial damage in podocytes.

**PAN-induced MCNS is related to mitochondrial damage**

Only a few studies have attempted to assess mitochondrial morphology quantitatively in the kidney using electron microscopy [14, 35]. Sweetwyne *et al.* observed mitochondria in podocytes of aged mice with or without antioxidant therapy and classified the degree of mitochondrial damage using a score of 1–5 (a higher number indicating worse damage) [35]. Using this...
scoring method, we demonstrated that the mitochondrial damage in podocytes was significantly less severe in the PAN + MitoTEMPO group than in the PAN group, proving that MitoTEMPO reduced the amount of mitochondrial ROS, the extent of mitochondrial damage in podocytes, the degree of foot process effacement, and excretion of urinary protein. We did not directly measure mitochondrial ROS or ROS only in podocytes. However, as the ROS surge in podocytes led to MCNS, and MitoTEMPO is a radical scavenger specific to mitochondria and reduces the degree of mitochondrial damage, it appears that podocyte mitochondrial ROS and subsequent damage are related to the disease state in MCNS. We suggest that the course of events in the PAN + MitoTEMPO group was as follows: (i) PAN caused a ROS surge in podocytes leading to foot process effacement, (ii) MitoTEMPO was taken up by podocyte mitochondria, where it reduced ROS, and (iii) the amelioration of mitochondrial damage contributed to foot process recovery and reduction of urinary protein excretion. The action of MitoTEMPO in preventing mitochondrial ROS production and damage may have been due to its accumulation in the mitochondrial matrix, where many mechanisms related to production of ROS operate [36–41], thus allowing MitoTEMPO to suppress them.

In conclusion, we have demonstrated that use of an antioxidant agent specific for mitochondria is able to reduce the amount of mitochondrial ROS, ameliorate mitochondrial damage in podocytes and reduce daily urinary protein excretion in an in vivo MCNS model. As the present study has revealed that mitochondrial oxidative stress plays a role in the disease state

**Fig 7. Representative images of mitochondria in the NS, PAN, and PAN + MitoTEMPO groups.** Mitochondrial morphological changes in podocytes due to PAN and MitoTEMPO were observed by electron microscopy. In the PAN group, some of the mitochondrial cristae were absent, the matrix density was low in some areas, and the outer and inner membranes were separated. However, such features were not evident in the PAN + MitoTEMPO group. NS = normal saline; PAN = puromycin aminonucleoside.

https://doi.org/10.1371/journal.pone.0227414.g007
of MCNS, we conclude that this type of mitochondrion-targeting radical scavenger may have considerable utility for reducing both mitochondrial damage and urinary protein excretion in MCNS.

Acknowledgments

We are grateful to Yuri Ito and Keisuke Fukui for expert comments on statistical analysis, Kazumi Honda, Jun Shinohara and Yoshihiko Fujioka for technical assistance, Mitsuru Nakajima for important advice on electron microscopy, Keishi Naruse for expert comments on pathology, and Kazuya Hirano for valuable comments.

Author Contributions

Conceptualization: Yuko Fujii, Akira Ashida.
Data curation: Yuko Fujii, Hideki Matsumura, Satoshi Yamazaki, Akihiko Shirasu, Hyogo Nakakura, Tohru Ogihara, Akira Ashida.
Formal analysis: Yuko Fujii, Akira Ashida.
Funding acquisition: Akira Ashida.
Investigation: Yuko Fujii, Hideki Matsumura, Satoshi Yamazaki, Akihiko Shirasu, Hyogo Nakakura, Tohru Ogihara, Akira Ashida.
Methodology: Yuko Fujii.
Project administration: Yuko Fujii, Akira Ashida.
Software: Yuko Fujii.
Supervision: Hideki Matsumura, Akihiko Shirasu, Hyogo Nakakura, Tohru Ogihara, Akira Ashida.
Validation: Yuko Fujii, Satoshi Yamazaki, Akira Ashida.
Visualization: Yuko Fujii, Akira Ashida.
Writing – original draft: Yuko Fujii.
Writing – review & editing: Yuko Fujii, Hideki Matsumura, Satoshi Yamazaki, Akihiko Shirasu, Hyogo Nakakura, Tohru Ogihara, Akira Ashida.

References

1. Picone P, Nuzzo D, Caruana L, Scafidi V, Di Carlo M. Mitochondrial dysfunction: different routes to Alzheimer’s disease therapy. Oxid Med Cell Longev. 2014; 2014: 780179. https://doi.org/10.1155/2014/780179 PMID: 25221640
2. Ni R, Cao T, Xiong S, Ma J, Fan GC, Lacefield JC, et al. Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy. Free Radic Biol Med 2016; 90: 12–23. https://doi.org/10.1016/j.freeradbiomed.2015.11.013 PMID: 26577173
3. Lee SJ, Ryter SW, Xu JF, Nakahira K, Kim HP, Choi AM, et al. Carbon monoxide activates autophagy via mitochondrial reactive oxygen species formation. Am J Respir Cell Mol Biol 2011; 45: 867–873. https://doi.org/10.1165/rcmb.2010-0352OC PMID: 21441382
4. Novak EA, Mollen KP. Mitochondrial dysfunction in inflammatory bowel disease. Front Cell Dev Biol 2015; 3: 62. https://doi.org/10.3389/fcell.2015.00062 PMID: 26484345
5. Qian T, Nieminen AL, Herman B, Lermasters JJ. Mitochondrial permeability transition in pH-dependent reperfusion injury to rat hepatocytes. Am J Physiol 1997; 273: C1783–1792. https://doi.org/10.1152/ajpcell.1997.273.6.C1783 PMID: 9435481
6. Dong LF, Neuzil J. Mitochondria in cancer: why mitochondria are a good target for cancer therapy. Prog Mol Biol Transl Sci. 2014; 127: 211–227. https://doi.org/10.1016/B978-0-12-394625-6.00008-8 PMID: 25149219

7. Patil NK, Parajuli N, MacMillan-Crow LA, Mayeux PR. Inactivation of renal mitochondrial respiratory complexes and manganese superoxide dismutase during sepsis: mitochondria-targeted antioxidant mitigates injury. Am J Physiol Renal Physiol. 2014; 306: F734–743. https://doi.org/10.1152/ajprenal.00643.2013 PMID: 2450690

8. Cui J, Bai XY, Sun X, Cai G, Hong Q, Ding R, et al. Rapamycin protects against gentamicin-induced acute kidney injury via autophagy in mini-pig models. Sci Rep 2015; 5: 11256. https://doi.org/10.1038/srep11256 PMID: 2605290

9. Lin CH, Chang LW, Wei YH, Wu SB, Yang CS, Chang WH, et al. Electronic microscopy evidence for mitochondria as targets for Cd/Se/Te-based quantum dot 705 toxicity in vivo. Kaohsiung J Med Sci. 2012; 28: SS3–62. https://doi.org/10.1016/j.kjms.2012.05.011 PMID: 22871604

10. Zhu C, Huang S, Yuan Y, Ding G, Chen R, Liu B, et al. Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ. Am J Pathol. 2011; 178: 2020–2031. https://doi.org/10.1016/j.ajpath.2011.01.029 PMID: 21514419

11. Holthöfer H, Kretzler M, Haltia A, Solin ML, Taanman JW, Schägger H, et al. Altered gene expression and functions of mitochondria in human nephrotic syndrome. FASEB J. 1999; 13: 523–532. https://doi.org/10.1096/fasebj.13.3.523 PMID: 10064619

12. Che R, Zhu C, Ding G, Zhao M, Bai M, Jia Z, et al. Huai'er cream protects against adriamycin-induced nephropathy by restoring mitochondrial function via PGC-1α upregulation. PPAR Res. 2015; 2015: 720383. https://doi.org/10.1155/2015/720383 PMID: 26804019

13. Emma F, Montini G, Parikh SM, Salviati L. Mitochondrial dysfunction in inherited renal disease and acute kidney injury. Nat Rev Nephrol. 2016; 12: 267–280. https://doi.org/10.1038/nrneph.2015.214 PMID: 26804019

14. Guan N, Ren YL, Liu XY, Zhang Y, Pei P, Zhu SN, et al. Protective role of cyclosporine A and minocycline on mitochondrial disequilibrium-related podocyte injury and proteinuria occurrence induced by adriamycin. Nephrol Dial Transplant. 2015; 30: 957–969. https://doi.org/10.1093/ndt/gfv015 PMID: 25646018

15. Hotta O, Inoue CN, Miyabayashi S, Furuta T, Takeuchi A, Taguma Y. Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial IRNLeu(UUR) gene mutation. Kidney Int. 2001; 59: 1236–1243. https://doi.org/10.1046/j.1523-1755.2001.0590041236.x PMID: 11260383

16. Czajka A, Ajaz S, Grudzi, L. Parsade CK, Jones P, Reid F, et al. Altered mitochondrial function, mitochondrial DNA and reduced metabolic flexibility in patients with diabetic nephropathy. EBioMedicine. 2015; 2: 499–512. https://doi.org/10.1016/j.ebiom.2015.04.002 PMID: 26288815

17. Szabolcs MJ, Seigle R, Shanske S, Bonilla E, DiMauro S, D’Agati V. Mitochondrial DNA deletion: a cause of chronic tubulointerstitial nephropathy. Kidney Int. 1994; 45: 1388–1396. https://doi.org/10.1038/ki.1994.181 PMID: 8072250

18. Granata S, Dalla Gassa A, Tomei P, Lupo A, Zaza G. Mitochondria: a new therapeutic target in chronic kidney disease. Nutr Metab (Lond.) 2015; 12: 49.

19. Kezic A, Spasovic I, Lezaic V, Bajcetic M. Mitochondria-targeted antioxidants: Future perspectives in kidney ischemia-reperfusion injury. Oxid Med Cell Longev. 2016; 2016: 2950530. https://doi.org/10.1155/2015/2950530 PMID: 27313826

20. Papazova DA, Friederich-Persson M, Joles JA, Verhaar MC. Renal transplantation induces mitochondrial uncoupling, increased kidney oxygen consumption, and decreased kidney oxygen tension. Am J Physiol Renal Physiol. 2015; 308: F22–28. https://doi.org/10.1152/ajprenal.00278.2014 PMID: 25275014

21. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, et al. Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res. 2010; 107: 106–116. https://doi.org/10.1161/CIRCRESAHA.109.214601 PMID: 20448215

22. Rocha VC, França LS, de Araújo CF, Ng AM, de Andrade CM, Andrade AC, et al. Protective effects of mito-TEMPO against doxorubicin cardiotoxicity in mice. Cancer Chemother Pharmacol. 2016; 77: 659–662. https://doi.org/10.1007/s00280-015-2949-7 PMID: 26712129

23. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med. 2011; 51: 1289–1301. https://doi.org/10.1016/j.freeradbiomed.2011.06.033 PMID: 21777669

24. Ademowo OS, Dias HKI, Burton DGA, Griffiths HR. Lipid (per) oxidation in mitochondria: an emerging target in the ageing process? Biogerontology 2017; 18: 859–879. https://doi.org/10.1007/s10522-017-9710-z PMID: 28540446
25. Gwinner W, Landmesser U, Brandes RP, Kubat B, Plasger J, Eberhard O, et al. Reactive oxygen species and antioxidant defense in puromycin aminonucleoside glomerulopathy. J Am Soc Nephrol. 1997; 8: 1722–1731. PMID: 9355075

26. Vega-Warner V, Ransom RF, Vincent AM, Brosius FC, Smoyer WE. Induction of antioxidant enzymes in murine podocytes precedes injury by puromycin aminonucleoside. Kidney Int. 2004; 66: 1881–1889. https://doi.org/10.1111/j.1523-1755.2004.00962.x PMID: 15496159

27. Nakakura H, Ashida A, Hirano K, Tamai H. Oxidative stress in a rat model of nephrosis can be quantified by electron spin resonance. Pediatr Nephrol 2004; 19: 266–270. https://doi.org/10.1007/s00467-003-1332-9 PMID: 14714169

28. Matsumura H, Ashida A, Hirano K, Nakakura H, Tamai H. Protective effect of radical scavenger edaravone against puromycin nephrosis. Clin Nephrol. 2006; 66: 405–410. PMID: 17176911

29. Takayasu Y, Nakaji K, Kawasaki T, Koda K, Aoyama Y, Baba A, et al. Edaravone, a radical scavenger, inhibits mitochondrial permeability transition pore in rat brain. J Pharmacol Sci. 2007; 103: 434–437. https://doi.org/10.1254/jphs.sc1070014 PMID: 17409627

30. Zhang ZW, Xu XC, Liu T, Yuan S. Mitochondrion-permeable antioxidants to treat ROS-burst-mediated acute diseases. Oxid Med Cell Longev. 2016; 2016: 685923. https://doi.org/10.1155/2016/6859523 PMID: 26649144

31. Shen X, Jiang H, Ying M, Xie Z, Li X, Wang H, et al. Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. Sci Rep. 2016; 6: 32087. https://doi.org/10.1038/srep32087 PMID: 27580845

32. Li X, Tao H, Xie K, Ni Z, Yan Y, Wei K, et al. cAMP signaling prevents podocyte apoptosis via activation of protein kinase A and mitochondrial fusion. PLoS One 2014; 9: e92003. https://doi.org/10.1371/journal.pone.0092003 PMID: 24642777

33. Hasegawa M, Ogihara T, Tamai H, Hiroi M. Hypothermic inhibition of apoptotic pathways for combined neurotoxicity of iron and ascorbic acid in differentiated PC12 cells: reduction of oxidative stress and maintenance of the glutathione redox state. Brain Res. 2009; 1283: 1–13. https://doi.org/10.1016/j.brainres.2009.06.016 PMID: 19524561

34. Sesso A, Belizário JE, Marques MM, Higuchi ML, Schumacher RI, Colquhoun A, et al. Mitochondrial swelling and incipient outer membrane rupture in preapoptotic and apoptotic cells. Anat Rec. (Hoboken) 2012; 295: 1647–1659.

35. Sweetwyne MT, Pippin JW, Eng DG, Hudkins KL, Chiao YA, Campbell MD, et al. The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age. Kidney Int. 2017; 91: 1126–1145. https://doi.org/10.1016/j.kint.2016.10.036 PMID: 28063595

36. Picard M, Shinhai OS, Gentil BJ, Burelle Y. Mitochondrial morphology transitions and functions: implications for retrograde signaling? Am J Physiol Regul Integr Comp. Physiol. 2013; 304: R395–406. https://doi.org/10.1152/ajpregu.00584.2012 PMID: 23364527

37. Gunter TE, Yule DI, Gunter KK, Eliseev RA, Saltar JD. Calcium and mitochondria. FEBS Lett. 2004; 567: 96–102. https://doi.org/10.1016/j.febslet.2004.03.071 PMID: 15165900

38. Gunter TE, Sheu SS. Characteristics and possible functions of mitochondrial Ca\textsuperscript{2+} transport mechanisms. Biochim Biophys Acta. 2009; 1787: 1291–1308. https://doi.org/10.1016/j.bbaba.2008.12.011 PMID: 19161975

39. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-induced ROS release: An update and review. Biochim Biophys Acta. 2006; 1757: 509–517. https://doi.org/10.1016/j.bbabio.2006.04.029 PMID: 16829228

40. Aon MA, Cortassa S, Akar FG, O’Rourke B. Mitochondrial criticality: a new concept at the turning point of life or death. Biochim Biophys Acta 2006; 1762: 232–240. https://doi.org/10.1016/j.bbadis.2005.06.008 PMID: 16242921

41. Siemen D, Ziemer M. What is the nature of the mitochondrial permeability transition pore and what is it not? IUBMB Life 2013; 65: 255–262. https://doi.org/10.1002/iub.1130 PMID: 23341030